Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Program 1
- Development stage
- Preclinical
- Lead developer
- Forward Therapeutics
01
Overview
Program 1 is an early-stage drug development program within the pipeline of Forward Therapeutics. While the company's lead candidates, such as FT751 and FT2109, are small molecule inhibitors targeting soluble Tumor Necrosis Factor (sTNF) and TNF Receptor 1 (TNFR1) for the treatment of inflammatory and autoimmune diseases, the specific biological targets, therapeutic modalities, and intended indications for Program 1 remain undisclosed. The program represents the company's broader research efforts to identify and develop next-generation therapies for chronic inflammation-driven conditions.
- Other names
- Forward Therapeutics-Multiple targets (undisclosed)
Beyond the preview
Go deeper on Program 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Program 1.